Cargando…
Retracted: Metformin Synergizes with PD-L1 Monoclonal Antibody Enhancing Tumor Immune Response in Treating Non-Small Cell Lung Cancer and Its Molecular Mechanism Investigation
Autor principal: | and Alternative Medicine, Evidence-Based Complementary |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412184/ https://www.ncbi.nlm.nih.gov/pubmed/37565233 http://dx.doi.org/10.1155/2023/9871939 |
Ejemplares similares
-
Retracted: Risk Factors for Thyroid Dysfunction in Patients with Advanced Non-Small-Cell Lung Cancer Treated with PD-1 Antibody
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023) -
Retracted: Comparative Analysis of Clinical Effects of Insulin Aspart Combined with Acarbose and Metformin in the Treatment of Diabetes Mellitus
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023) -
Retracted: Expression of PD-L1 and BRCA1 in Triple-Negative Breast Cancer Patients and Relationship with Clinicopathological Characteristics
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023) -
Retracted: Advantages of Small Incision Surgery in Thyroid Tumors
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023) -
Retracted: High CHAF1A Expression Levels Are Positively-Correlated with PD-L1 Expression and Indicate Poor Prognosis in Gastric Cancer
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)